Despite strong tumor-supporting activity identified for several members of SR-A family expressed by TAMs (26, 27, 30, 32, 33), solid body of evidence is available for SR-A1 and SR-A6 demonstrating their anti-tumor action that depends primarily on the cancer types (20–22, 28) (Figure 3, Table 1). Here, MARCO is linked to neoplasm.